Symptomatic improvement typically begins 2–4 weeks post-infusion and progresses over 8–12 weeks. Functional gains plateau by 5–6 months. Follow-up studies extending to 12–24 months show sustained benefit in approximately 60% of initial responders; others experience gradual symptom recurrence. Some patients require repeat treatment cycles; optimal re-dosing intervals remain unclear.
Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection. Proposed mechanisms include persistent viral fragments in reservoir tissues, endothelial activation with microclot formation, dysregulated immune memory (skewed Th1/Th17 responses, reduced regulatory T cells), and mitochondrial dysfunction. Placental mesenchymal stem cells and exosomes address these pathways through endothelial repair, anti-inflammatory cytokine secretion, and metabolic rescue of dysfunctional immune cells. Eleven registered clinical trials and two actively recruiting protocols evaluate MSC and exosome infusions in long-COVID cohorts, predominantly focusing on severe functional impairment or cardiopulmonary involvement.
我是候选人吗？ → · Long COVID: full overview → · 长期COVID成本 → · Cost →
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估